12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AT13387: Phase I/II started

Astex began the open-label Phase I/II AT13387-04 trial to evaluate AT13387 in up to 164 CRPC patients who have progressed after treatment with Zytiga abiraterone and steroids. The Phase I portion will evaluate 2 doses...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >